In wich countries can have acces to pomalyst?

Pomalyst (the branded form of the drug pomalidomide) is a prescription medication approved for the treatment of multiple‑myeloma (usually after other therapies have failed). Its availability depends on whether the drug has been approved by the regulatory authority in each country. Below is a quick reference of the major regions where Pomalyst is approved and typically obtainable (as of 2026):

Note:
• The above list reflects the approved status as of 2026.
• In many countries the drug is supplied through specialty pharmacies or oncology clinics rather than standard retail pharmacies.
• Some nations may have the drug under a different brand name (e.g., generic pomalidomide) but the active ingredient is the same.

How to Verify Availability in Your Country

1. Check the local drug regulatory authority (e.g., FDA, EMA, PMDA, TGA, Health Canada, etc.) for a list of approved medicines.
2. Consult a local oncologist or pharmacist; they can tell you if Pomalyst is on the hospital formulary or available via a specialty pharmacy.
3. Specialty pharmacy networks (e.g., PomaCare in the U.S., Pomalyst Access Program in the EU) often assist patients who need the drug but live in a region without direct availability.

Bottom Line

Pomalyst is available in the vast majority of high‑income countries that have a robust regulatory framework for oncology drugs—especially the U.S., EU, Canada, Australia, Japan, and several Latin American and Asian markets. If you’re outside those regions, the drug may still be obtainable through international pharmaceutical distributors, but you’ll need to check local approval status and possibly importation rules. Always discuss with a qualified health professional before starting any new cancer therapy.